Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3992 Recurrence free survival and disease-specific survival in patients with pancreatic neuroendocrine neoplasms: A single center retrospective study of 413 patients

Introduction: The prognosis and impact of different prognostic factors in pancreatic neuroendocrine neoplasms (pNEN) remains controversial.

Conference:

Presenting Author: Andreassen M

Authors: Møller S, Langer S, Slott C, Krogh J, Palnæs Hansen C,

Keywords: Pancreatic neuroendocrine neoplasms incidence, clinical presentation, prognosis,

#472 Detection of Liver Metastases and Prognostic Value of Functional and Anatomical Imaging in Patients with Neuroendocrine Tumors

Introduction: Liver metastases (LM) are frequent in patients with neuroendocrine tumors (NETs) and are associated with decreased overall survival (OS). Several treatment options are available depending on degree, localization, size and number of LM. For optimal choice of treatment and correct staging, accurate imaging modalities are crucial.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Knigge U, Binderup T, Federspiel B, Palnæs Hansen C, Loft A,

Keywords: ,

#470 Overall Survival of Well-Differentiated Neuroendocrine Tumors Evaluated by F-18-FDG-PET

Introduction: Today, grading, and thereby choice of treatment strategy for patients with neuroendocrine (NE) tumors, is mainly based on the proliferation index, Ki-67. As a supplement to this pathological evaluation, a whole body image analysis could be of value.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Binderup T, Knigge U, Federspiel B, Palnæs Hansen C, Loft A,

Keywords: Survival, FDG-PET, WHO grade I & II,

#268 Temozolomide as 2.-3. line Treatment of Patients with Poorly Differentiated Neuroendocrine Carcinomas

Introduction: Knowledge of the clinical efficacy of treatment beyond first line of poorly differentiated neuroendocrine carcinomas (PDEC) is sparse. Temozolomide (TMZ) has shown effect in well-differentiated NET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Olsen I, Federspeil B, Kjaer A, Palnæs Hansen C, Knigge U,

Keywords: PDEC, poorly differentiated carcinomas, temozolomide, second line treatment,

#138 The use of F-18-FDG-PET for patients with neuroendocrine tumors

Introduction: Neoplastic tissue exhibits high glucose utilization, which can be imaged by 18F-Fluorodeoxyglucose-positron emission tomography (FDG-PET). Whether FDG-PET is useful for neuroendocrine (NE) tumors, however, is questionable, due to the slow growth rate often observed in these tumors.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Binderup T

Authors: Binderup T, Knigge U, Pfeifer A, Federspiel B, Palnæs Hansen C,

Keywords: neuroendocrine tumors, F-18-FDG-PET, proliferation index,